{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981470478807936.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa043470"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043470"}},{"identifier":{"@type":"NAID","@value":"30022563036"}}],"dc:title":[{"@value":"Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981470478807948","@type":"Researcher","foaf:name":[{"@value":"George K.K. Lau"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807942","@type":"Researcher","foaf:name":[{"@value":"Teerha Piratvisuth"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807941","@type":"Researcher","foaf:name":[{"@value":"Kang Xian Luo"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807943","@type":"Researcher","foaf:name":[{"@value":"Patrick Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807937","@type":"Researcher","foaf:name":[{"@value":"Satawat Thongsawat"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807808","@type":"Researcher","foaf:name":[{"@value":"Graham Cooksley"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807946","@type":"Researcher","foaf:name":[{"@value":"Edward Gane"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807939","@type":"Researcher","foaf:name":[{"@value":"Michael W. Fried"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807936","@type":"Researcher","foaf:name":[{"@value":"Wan Cheng Chow"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807949","@type":"Researcher","foaf:name":[{"@value":"Seung Woon Paik"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807938","@type":"Researcher","foaf:name":[{"@value":"Wen Yu Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807940","@type":"Researcher","foaf:name":[{"@value":"Thomas Berg"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807944","@type":"Researcher","foaf:name":[{"@value":"Robert Flisiak"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807947","@type":"Researcher","foaf:name":[{"@value":"Philip McCloud"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470478807945","@type":"Researcher","foaf:name":[{"@value":"Nigel Pluck"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2005-06-30","prism:volume":"352","prism:number":"26","prism:startingPage":"2682","prism:endingPage":"2695"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043470"}],"createdAt":"2005-06-29","modifiedAt":"2024-01-27","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050001202536339328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002217145497728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232280670208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232550879360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235963698176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142418892032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360022305560636288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Understanding hepatitis B virus dynamics and the antiviral effect of interferon-α treatment in humanized chimeric mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322536960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with <scp>HB</scp>eAg‐positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285712601754624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714657048832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714664842368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617829657088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214486272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185916732416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232188278784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Possible biological mechanisms of entecavir <i>versus</i> tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232420830080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643463251456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848655057424128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657213536896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664425007744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377081472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814738709120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204794898944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎創薬研究の最前線"},{"@language":"en","@value":"Recent advances in hepatitis B research and drug development"},{"@language":"ja-Kana","@value":"Bガタ カンエンソウヤク ケンキュウ ノ サイゼンセン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795197696","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir"},{"@language":"ja","@value":"エンテカビル・ペグインターフェロンα－２ｂ併用４８週治療にてＨＢｓ抗原が消失したＢ型慢性肝炎の１例"},{"@value":"症例報告 エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク エンテカビル ・ ペグインターフェロンa-2b ヘイヨウ 48シュウ チリョウ ニテ HBs コウゲン ガ ショウシツ シタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390005667263489664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771702272","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients"},{"@language":"ja","@value":"B型慢性肝炎患者に対するペグインターフェロンα-2aの有効性及び安全性の検討"},{"@language":"ja-Kana","@value":"Bガタ マンセイ カンエン カンジャ ニ タイスル ペグインターフェロンa-2a ノ ユウコウセイ オヨビ アンゼンセイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772498432","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化；HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"en","@value":"Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFNα-2a treatment after surgery for hepatocellular carcinoma: a case report"},{"@value":"症例報告 肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化 : HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク カンハツガン ゴ ニ Peg-IFNa-2a トウヨ ニ ヨリ HBs コウゲン インセイカ : HBs コウタイ ヨウセイカ ガ エラレタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681377615360","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎の治療-遺伝子型と治療について-"},{"@language":"en","@value":"Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681421863424","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Forefront of Treatment of Type B/C Chlonic Hepatitis."},{"@language":"ja","@value":"B型・C型慢性肝炎治療の最前線"},{"@value":"医学と医療の最前線 B型・C型慢性肝炎治療の最前線"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン Bガタ Cガタ マンセイ カンエン チリョウ ノ サイゼンセン"}]},{"@id":"https://cir.nii.ac.jp/crid/1520572358717382912","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"分科会委員会報告 小児B型肝炎の診療指針"},{"@language":"ja-Kana","@value":"ブンカカイ イインカイ ホウコク ショウニ Bガタ カンエン ノ シンリョウ シシン"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750573172608","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus genotypes in Europe"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225550106880","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700526864512","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Management of HBV infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550386807424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improving outcomes for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975837321088","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa043470"},{"@type":"CIA","@value":"30022563036"},{"@type":"CROSSREF","@value":"10.1074/jbc.m114.602540_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1128/aac.00725-17_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.42_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.58.217_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.57.666_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1016/j.jiac.2014.12.003_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1002/hep.31712_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1101/2020.07.28.224840_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/liv.13046_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0198264_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2009.12.036_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.135_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/hepr.13552_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1128/jvi.00492-20_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1189-x_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1128/aac.00183-17_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2169/naika.99.3080_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.3851/imp3225_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/jgh.16178_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.3390/v14112468_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1136/gutjnl-2016-312653_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1002/hep.27962_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.3390/ijms19071940_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1016/j.virusres.2012.10.027_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1111/hepr.13768_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1007/s00535-023-02070-y_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0216139_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5432-20_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"},{"@type":"CROSSREF","@value":"10.3892/br.2017.944_references_DOI_ISzkkBjOiwXByStMupVV8ibKGVz"}]}